01 — At a Glance
The Narrative vs. The Numbers: A Story In Two Acts
- 52-Week High / Low₹125 / ₹32.9
- Q3 FY26 Revenue₹101 Cr
- Q3 FY26 PAT₹19.2 Cr
- TTM EPS₹0.61
- Annualised EPS (Q3 Avg × 4)₹1.20
- Book Value / Share₹5.55
- Price to Book6.09x
- Operating CF (FY25)-₹87 Cr
- Working Capital Days40 days
- Total Assets (Sep 2025)₹468 Cr
Flash Summary: Fischer Medical just delivered Q3 FY26 PAT of ₹19.2 crore — up 6,731% YoY from ₹0.3 crore. Revenue jumped 760% to ₹101 crore. The story is slick: proprietary MRI tech, FDA approvals, government contracts, global expansion. But the stock crashed 74% from peak (₹125 → ₹32.9). Operating cash flow is negative ₹87 crore. The Company Secretary just resigned. Working capital cycles are suspiciously tight. P/E is 55.3x. ROE is 0.70%. Something doesn’t add up — and the market has noticed.
02 — Introduction
On Paper, A Healthcare Unicorn. In Practice, A Working Capital Treadmill.
Fischer Medical Ventures started as a nothing—literally incorporated in 1993 as a laboratory chemicals trader generating close to zero revenue for three decades. Then something shifted. Around 2023-24, the company pivoted hard. It partnered with (or acquired) Time Medical Systems, a Singapore-based MRI manufacturer with 20+ years of R&D and partnerships with Columbia University and Harvard Medical School. Suddenly, revenue started flowing. From ₹0 in Mar 2023 to ₹21 Cr (Mar 2024) to ₹111 Cr (Mar 2025) to ₹260 Cr TTM. That’s growth on steroids.
The investor presentation reads like a Silicon Valley fever dream: proprietary permanent-magnet MRI technology, helium-free superconductor systems, CDSCO-approved devices, FDA clearances, AI-powered diagnostic kiosks (FlynnCare), global partnerships in Indonesia, Philippines, Malaysia, and Singapore. The team includes ex-Harvard researchers, ex-GE executives, and government luminaries (ex-Malaysian Health Minister, ex-Philippine Governor). Order books exceed ₹100 crore. Government tenders are being won. The vision is compelling: decentralize and democratize healthcare diagnostics across emerging markets.
Then you look at the actual financials. Operating cash flow: -₹87 crore in FY25 despite ₹111 crore revenue. Working capital compression from 498 days to 40 days (suspiciously fast). Debtors at 251 days (government customers paying slowly). Borrowings jumped from ₹2 Cr to ₹85 Cr to ₹30 Cr (erratic). A ₹40 crore HDFC Bank loan with shares pledged (January 2026). Company Secretary resigned. Stock crashed 70% in six months despite “record quarters.” P/E at 55.3x while ROE is 0.70%. The market is asking: Is this real revenue or accounting timing? Real growth or a capital-raise treadmill?
The Core Question: Is Fischer Medical a transformational healthcare infrastructure play that the market is temporarily panicking about? Or is it a company on a financing treadmill, booking revenue on extended credit terms to government customers, and masking negative cash flow with shareholder dilution?
03 — Business Model: WTF Do They Actually Do?
Diagnosis Devices + Health Screening Kiosks + Digital Platforms = Chaos Or Genius?
Members get full access to every article.
